Olivo Alicia C 4
4 · NEOGENOMICS INC · Filed Feb 24, 2026
Research Summary
AI-generated summary of this filing
Neogenomics (NEO) EVP Alicia Olivo Exercises Options; Shares Withheld
What Happened Alicia C. Olivo, EVP, General Counsel & Business Development at Neogenomics (NEO), had derivative awards convert into 29,522 shares in two vesting/conversion events (Feb 21 and Feb 23, 2026). Of those, 11,618 shares were withheld to satisfy tax withholding obligations, resulting in a net increase of 17,904 shares to her beneficial ownership. All reported share prices are $0.00, consistent with conversion/vesting rather than an open-market purchase.
Key Details
- Transaction dates: Feb 21, 2026 (21,079 shares converted; 8,295 shares withheld) and Feb 23, 2026 (8,443 shares converted; 3,323 shares withheld).
- Gross shares acquired by conversion: 29,522; shares withheld for taxes: 11,618; net shares received: 17,904.
- Price per share reported: $0.00 (reflects vesting/conversion, not a cash purchase).
- Transaction codes: M = exercise/conversion of derivative; F = payment of exercise price or tax liability (share withholding).
- Footnote F2 confirms the disposals were withholding of common stock to satisfy tax obligations related to issuance upon release of restricted stock units. Other footnotes list prior option/RSU/PSU grants (2022–2025) that likely produced the vested/converted shares.
- Filing date: Feb 24, 2026 (covering transactions on/through Feb 21–23, 2026).
Context These transactions are routine vesting/conversion events (derivative conversion of RSUs/options) rather than open-market buys or sales. Withholding shares to cover taxes is a common administrative step and does not necessarily signal a change in insider sentiment. For clarity: M = conversion/exercise of a derivative (e.g., vested RSU or exercised option) and F = shares withheld to pay taxes.
Insider Transaction Report
Form 4
Olivo Alicia C
EVP, GC & Business Development
Transactions
- Exercise/Conversion
Common Stock
[F1]2026-02-21+21,079→ 96,399 total - Tax Payment
Common Stock
[F2]2026-02-21−8,295→ 88,104 total - Exercise/Conversion
Common Stock
[F1]2026-02-23+8,443→ 96,547 total - Tax Payment
Common Stock
[F2]2026-02-23−3,323→ 93,224 total - Exercise/Conversion
Restricted Stock Unit
[F3][F4]2026-02-21−21,079→ 42,159 totalExercise: $0.00→ Common Stock (21,079 underlying) - Exercise/Conversion
Restricted Stock Unit
[F5][F4]2026-02-23−8,443→ 8,443 totalExercise: $0.00→ Common Stock (8,443 underlying)
Holdings
- 1,046
Stock Option (Right to Buy)
[F6]Exercise: $19.12Exp: 2026-09-30→ Common Stock (1,046 underlying) - 1,024
Stock Option (Right to Buy)
[F7]Exercise: $27.34Exp: 2027-05-01→ Common Stock (1,024 underlying) - 516
Stock Option (Right to Buy)
[F8]Exercise: $48.99Exp: 2028-05-01→ Common Stock (516 underlying) - 1,117
Stock Option (Right to Buy)
[F9]Exercise: $46.10Exp: 2028-08-01→ Common Stock (1,117 underlying) - 22,222
Stock Option (Right to Buy)
[F10]Exercise: $9.45Exp: 2029-05-01→ Common Stock (22,222 underlying) - 46,355
Stock Option (Right to Buy)
[F11]Exercise: $10.05Exp: 2029-09-01→ Common Stock (46,355 underlying) - 36,508
Stock Option (Right to Buy)
[F12]Exercise: $19.65Exp: 2030-05-11→ Common Stock (36,508 underlying) - 6,503
Restricted Stock Unit
[F13][F4]Exercise: $0.00→ Common Stock (6,503 underlying) - 19,508
Performance Stock Unit
[F14][F4]Exercise: $0.00From: 2026-05-11→ Common Stock (19,508 underlying) - 42,344
Stock Option (Right to Buy)
[F15]Exercise: $16.45Exp: 2034-02-23→ Common Stock (42,344 underlying) - 59,382
Restricted Stock Unit
[F4]Exercise: $0.00From: 2026-01-13→ Common Stock (59,382 underlying) - 25,330
Performance Stock Unit
[F16][F4]Exercise: $0.00From: 2027-02-23→ Common Stock (25,330 underlying) - 107,450
Stock Option (Right to Buy)
[F17][F18]Exercise: $13.05Exp: 2035-02-21→ Common Stock (107,450 underlying)
Footnotes (18)
- [F1]Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting.
- [F10]On May 1, 2022, Ms. Olivo was granted 22,222 stock options. The options vest ratably over the first four anniversary dates of the grant date.
- [F11]On September 1, 2022, Ms. Olivo was granted 55,332 stock options. The options vest ratably over the first four anniversary dates of the grant date.
- [F12]On May 11, 2023, Ms. Olivo was granted 36,508 stock options. The options vest ratably over the first three anniversary dates of the grant date.
- [F13]On May 11, 2023, Ms. Olivo was granted 19,508 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
- [F14]On May 11, 2023, Ms. Olivo was granted 19,508 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 29,262. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at theapplicable measurement dates, subject to continued service with the Company.
- [F15]On February 23, 2024, Ms. Olivo was granted 42,344 stock options. The options vest ratably over the first three anniversary dates of the grant date.
- [F16]On February 23, 2024, Ms. Olivo was granted 25,330 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is37,996. 50% of the number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period atthe applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of thecumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company.
- [F17]This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 20, 2025 and multiplied by 110%.
- [F18]On February 21, 2025, Ms. Olivo was granted 107,450 stock options. The options vest ratably over the first three anniversary dates of the grant date.
- [F2]Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units.
- [F3]On February 21, 2025, Ms. Olivo was granted 63,238 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
- [F4]Once vested, the shares of common stock are not subject to expiration.
- [F5]On February 23, 2024, Ms. Olivo was granted 25,329 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
- [F6]On September 30, 2019, Ms. Olivo was granted 1,394 stock options. The options vest ratably over the first four anniversary dates of the grant date.
- [F7]On May 1, 2020, Ms. Olivo was granted 1,024 stock options. The options vest ratably over the first four anniversary dates of the grant date.
- [F8]On May 1, 2021, Ms. Olivo was granted 516 stock options. The options vest ratably over the first four anniversary dates of the grant date.
- [F9]On August 1, 2021, Ms. Olivo was granted 1,117 stock options. The options vest ratably over the first four anniversary dates of the grant date.
Signature
/s/ Alicia C. Olivo|2026-02-24